Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Lineage Cell Therapeutics advanced its preclinical COR1 program into in-vivo animal testing for corneal endothelial disease, aiming to address donor shortages. The company successfully utilized its proprietary AlloSCOPE platform to meet manufacturing thresholds for potency and scale, targeting a "thaw-and-inject" formulation to improve upon cadaver-derived cells.
Key figures
- Patient population 2020
- 300 million
- Annual keratoplasty demand
- 12.7 million cases
- Global transplant waitlist
- 13 million people
- Donor to diseased eye ratio
- 1 for every 70
- Us addressable market patients
- 2-6 million
- Global prevalence adults over 30
- 7.33%
- Patient population 2050 projected
- 415 million
- Europe addressable market patients
- 16 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.